{"id":"methylphenidate-extended-release-atomoxetine","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Insomnia"},{"rate":"15-25","effect":"Decreased appetite"},{"rate":"10-15","effect":"Headache"},{"rate":"5-10","effect":"Nausea"},{"rate":"5-10","effect":"Abdominal pain"},{"rate":"5-10","effect":"Dizziness"},{"rate":"5-10","effect":"Tachycardia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Methylphenidate blocks the reuptake of dopamine and norepinephrine at the presynaptic terminal, increasing their availability in the synaptic cleft. Atomoxetine selectively inhibits the norepinephrine transporter, leading to increased norepinephrine levels in the prefrontal cortex and other brain regions. Together, these mechanisms enhance attention, focus, and impulse control in patients with ADHD.","oneSentence":"Methylphenidate is a central nervous system stimulant that increases dopamine and norepinephrine activity, while atomoxetine is a selective norepinephrine reuptake inhibitor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:54:47.769Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Attention-deficit/hyperactivity disorder (ADHD) in children and adults"}]},"trialDetails":[{"nctId":"NCT01399827","phase":"PHASE2","title":"Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With Deficient Emotional Self-Regulation Traits","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2012-02","conditions":"Attention Deficit Hyperactivity Disorder (ADHD), Deficient Emotional Self-Regulation (DESR)","enrollment":2},{"nctId":"NCT01133847","phase":"PHASE4","title":"Interventions for Children With Attention and Reading Disorders","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2010-11","conditions":"Attention Deficit Hyperactivity Disorder, Reading Disabilities","enrollment":222},{"nctId":"NCT01624649","phase":"","title":"A Study to Examine the Progression of Attention-Deficit Hyperactivity Disorder (ADHD) Drug Treatment and to Analyze Associated Factors","status":"COMPLETED","sponsor":"Janssen Korea, Ltd., Korea","startDate":"2012-02","conditions":"Attention-deficit Hyperactivity Disorder","enrollment":289},{"nctId":"NCT02226445","phase":"","title":"Treatment Drop-out and Missed Appointments Among Adults With ADHD","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2010-09","conditions":"Attention-Deficit/Hyperactivity Disorder, Drop-out, Non-adherence","enrollment":153},{"nctId":"NCT00866996","phase":"PHASE4","title":"Community-based Study Comparing Extended-release Methylphenidate and Atomoxetine in Children With Attention-deficit Hyperactivity Disorder","status":"COMPLETED","sponsor":"McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.","startDate":"","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":1323},{"nctId":"NCT00485550","phase":"PHASE3","title":"Comparison of Atomoxetine Plus Either Comparator or Placebo in Children With ADHD Who Haven't Responded to Stimulant Therapy","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2004-01","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":14}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":68,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Methylphenidate extended-release; Atomoxetine","genericName":"Methylphenidate extended-release; Atomoxetine","companyName":"McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.","companyId":"mcneil-consumer-specialty-pharmaceuticals-a-division-of-mcneil-ppc-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Methylphenidate extended-release is used to treat Attention-Deficit/Hyperactivity Disorder (ADHD), as indicated by ClinicalTrials.gov. It works by inhibiting the sodium-dependent dopamine transporter, a mechanism of action supported by ChEMBL.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}